Project Grant R21AR084040
- This federal Project Grant award of $286,791, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop pediatric-specific blood transcriptional modules (pBTMs) that capture the broad range of heterogeneous physiological states in children across diverse geographical settings. The project will construct these modules using transcriptome data from over 13,000 samples across 76 studies...
- Cooperative Agreement Summary Boston Children's Hospital has received a Cooperative Agreement award of $9.55 million from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective August 19, 2025, with completion targeted for June 30, 2030, establishes the Immunization Against Multidrug-Resistant Pathogens: Activating T Cell Immunity Center of Excellence for Translational Research...
- This R21 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $433,950 to the University of California, Davis to study the impact of wildfire smoke exposure on lung injury and disease in pediatric populations. The key objectives are to: 1) Define the contribution of age on the toxicity of wood smoke particles in respiratory and alveolar epithelium, 2) Investigate the effect of early life wood...
- Federal Project Grant Award Summary Yale University received a $2.65 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, through May 31, 2030. The award supports the Predictors and Determinants of Pediatric Immunity (PEDS) program, which aims to elucidate the unique characteristics and developmental trajectories of the pediatric immune system. The research program...
- Federal Project Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded $498,000 through the Environmental Health program (CFDA 93.113) to Icahn School of Medicine at Mount Sinai on August 25, 2025, for a three-year project extending through July 31, 2028. This R00 Career Transition Award supports research investigating how prenatal exposure to fine particulate air pollution (PM2.5) influences neurodevelopmental outcomes in children. The investigator will...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a Project Grant totaling $135,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 16, 2025, with a completion date of June 30, 2030. This grant funds research led by Dr. Jelte Kelchtermans to develop predictive models and risk assessment tools for pediatric asthma exacerbations triggered by ambient air pollution (AAP)...
- Federal Grant Award Summary The National Institute of Environmental Health Sciences (NIEHS) awarded a $157,500 Project Grant to the Regents of the University of California at Riverside on July 9, 2025, under the Environmental Health program (CFDA 93.113). This two-year award (completion date: July 8, 2027) funds pilot research investigating gene-environment interactions in autism spectrum disorder (ASD) risk through developmental exposure to per- and polyfluoroalkyl substances (PFAS), commonly...
- Federal Cooperative Agreement Summary Cincinnati Children's Hospital Medical Center received a Cooperative Agreement award of $401,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 17, 2025, with an ultimate completion date of June 30, 2027. This award supports research investigating antibiotic-associated reactions (AAR) and serum sickness-like reactions (SSLR) in pediatric...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $3.15 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion targeted for August 31, 2029. The research project, titled "Dendritic Cell Intrinsic Unfolded Protein Response Is Critical for Pathogen-Specific Th17 Responses," focuses on...
- Federal Grant Award Summary The National Institute of Child Health and Human Development awarded The Children's Hospital of Philadelphia $767,069 on August 18, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct the Pediatric Acute Respiratory Distress Syndrome Management (PARMA) study through April 30, 2030. This project grant will investigate optimal ventilation management strategies for pediatric acute respiratory distress syndrome (ARDS), a...
PEDIATRIC AUTOIMMUNE CONSORTIUM FOR EXPOSOME RESEARCH (PACER) - PROJECT SUMMARY WHILE AUTOIMMUNE DISEASE (AID) OCCURS ACROSS THE LIFESPAN, THE EARLIEST SIGNS OF MANY AID CAN FIRST BE SEEN IN CHILDREN AND ADOLESCENTS. EARLY ONSET OF DISEASE CAN BE ASSOCIATED WITH MORE AGGRESSIVE COURSE AND THE RISK OF COMPLICATIONS ACCUMULATE OVER TIME. DESPITE DIVERSITY AMONGST DISEASE ENTITIES IN TERMS OF TISSUES AFFECTED AND RISK FACTORS FOR OCCURRENCE, IT IS STRIKING TO NOTE IMPORTANT COMMON THEMES IN PATHOGENIC FACTORS, FROM OVERLAP IN RISK GENES TO POTENTIAL ENVIRONMENTAL TRIGGERS. THE OVERALL RISING INCIDENCE OF AUTOIMMUNE DISEASES SUGGESTS ONGOING ENVIROMENAL CHANGES WHICH IMPACT RISK. UNDERSTANDING THE IMPACT OF MODIFIABLE EXPOSURES ON DISEASE PATHOGENESIS HAS THE POTENTIAL TO INFORM TARGETED INTERVENTIONS THAT COULD SLOW OR PREVENT THE DEVELOPMENT AND PROGRESSION OF THESE DISEASES IN CHILDREN AND LATER ADULTHOOD. WE PROPOSE TO DEVELOP A NEW, FIRST-OF-ITS-KIND TRANSDISPLINARY RESEARCH TEAM TO DEVELOPING THE INFRASTURCURE NEEDED TO FOR A FUTURE LARGE SCALE STUDY ON THE ROLE OF THE EXPOSOME IN CHILDHOOD AID. OUR OVERARCHING GOALS ARE TO: 1) ESTABLISH COLLABORATIVE PARTNERSHIPS TO LEVERAGE EXISTING COHORTS AND RESOURCES; 2) DEVELOP A MULTIDOMAIN, MULTILEVEL APPROACH TO COMPREHENSIVELY EXAMINE THE ROLE OF THE EXPOSOME ON AID PATHWAYS; AND 3) DEVELOP NOVEL STRATEGIES FOR INTEGRATING ENVIRONMENTAL FACTORS AND GENETIC DATA USING CUTTING- EDGE DATA SCIENCE METHODOLOGIES TO INVESTIGATE THE DEVELOPMENT AND PROGRESSION OF CHILDHOOD AID. OUR SPECIFIC AIMS ARE: AIM 1: TO ESTABLISH A MULTIDISCIPLINARY RESEARCH TEAM AND DEVELOP COLLABORATIVE PARTNERSHIPS FOR STUDYING THE EXPOSOME IN CHILDHOOD AID BY (1A) DEVELOPING A TRANSDISCIPLINARY CONSORTIUM ACROSS EXISTING STUDIES OF CHILDHOOD AID); (1B) CONDUCTING A LANDSCAPE ANALYSIS OF RELEVANT EXISTING RESOURCES; AND (1C) ORGANIZING TWO MULTIDAY WORKSHOPS TO DEVELOP AND EXPAND EXISTING RESEARCH AND COLLABORATIONS. AIM 2: EXPLORE STRATEGIES TO ADDRESS THE MULTIDOMAIN, MULTILEVEL APPROACH NEEDED TO COMPREHENSIVELY MEASURE THE EXPOSOME AND ASSESS CONSTRUCTS TO EVALUATE THEIR EFFECT ON DISEASE PATHWAYS IN CHILDREN WITH AID BY (2A) CONDUCTING A COMPREHENSIVE ANALYSIS OF EXISTING METHODS FOR MEASURING AND ANALYZING THE EARLY-LIFE EXPOSOME (2B) DEVELOP AND EXPAND DATA SCIENCE METHODS FOR INTEGRATING MULTIPLE DATA TYPES TO IDENTIFY PRECISE RISK PROFILES, AND (2C) DEMONSTRATE THE UTILITY OF THESE APPROACHES BY GENERATING PILOT ANALYSIS IN EXISTING DATA. AIM 3: DEVELOP AND IMPLEMENT RESEARCH INFRASTRUCTURE TO SUPPORT THE FUTURE EXACT EFFORT. IMPACT: THE PROPOSED RESEARCH ACTIVITIES WILL LAY THE FOUNDATIONS FOR FUTURE LARGE SCALE NATIONAL, INTERDISCIPLINARY, COLLABORATIVE RESEARCH NETWORK FOCUSED ON PERFORMING GROUNDBREAKING RESEARCH IN CHILDHOOD AID.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/4/25 | ||
| Not listed | $451.9k | 9/22/23 |